We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Accepts Sandoz Biosimilar Application for a Version of Amgen’s Neupogen
FDA Accepts Sandoz Biosimilar Application for a Version of Amgen’s Neupogen
More than four years after Congress allowed biosimilars, Sandoz said yesterday that the FDA had accepted its application for a biosimilar of Amgen’s Neupogen, a milestone in the race to develop the highly anticipated biological products.